Condition

Radiotherapy

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 64 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials64

Recruiting22

Common interventions25

Lead sponsors shown15

Clinical trials

60 shown

Low-dose Thoracic Radiotherapy Followed by Adebrelimab Plus Chemotherapy, and Then Sequential Maintenance Therapy With Adebrelimab for Extensive-stage Small Cell Lung CancerNCT07583550 · 2026-07-20

Establishment of a Prospective Clinical Cohort of Small Cell Lung Cancer Patients Receiving Radiotherapy-Involved Comprehensive TreatmentNCT07565532 · 2026-04-01

Targeted Induction Therapy for Stage III Unresectable EGFR Mutant Positive NSCLCNCT07742332 · 2025-11-25

Level I-II Axillary Irradiation in Breast Cancer With Sentinel-Node Macro-metastasesNCT07469267 · 2025-10-24

Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Malignant Solid TumorsNCT07071103 · 2025-09-26

Trastuzumab Rezetecan Combined With Radiotherapy Versus Trastuzumab Rezetecan in the Treatment of HER2-positive Advanced Breast Cancer With Brain MetastasesNCT07100600 · 2025-08-30

Spatially Fractionated Radiotherapy Combined With Immunotherapy for Advanced Solid TumorsNCT07058948 · 2025-07-01

Assessment of Adebelizumab Combined With Chemotherapy in Concurrent Radiotherapy Versus Sequential Radiotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung CancerNCT06768307 · 2025-01-07

The Impact of Metastatic Directed Radiotherapy (MDRT) on Oligoprogressive Castration Resistant Prostate Cancer (CRPC)NCT07038304 · 2025-01-03

Safety, Efficacy, and Survival Outcomes of Neoadjuvant/Induction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung CancerNCT06926179 · 2024-12-01

BRAVE-HEART: Breast Cancer Radiotherapy Using Active Breathing Coordinator to aVoid Exposure of HEARTNCT07299812 · 2024-05-23

Thoracic Radiotherapy for Patients With Metastatic (Stage IV) Non-Small Cell Lung Cancer at High Risk of Symptomatic Progression Within the ThoraxNCT06262321 · 2024-05-15

Primary Tumor Radiotherapy Omitting CTV for Patients With Advanced NSCLC Responded to Immunotherapy and ChemotherapyNCT06037733 · 2024-03-13

Omitting CTV for Locally Advanced NSCLC Responded to Immunotherapy and ChemotherapyNCT06020430 · 2024-02-08

A Randomized Trial of Five Fraction Partial Breast Irradiation (RAPID2)NCT05417516 · 2023-11-20

Efficacy and Safety of Super-hyperfractionation Pulse Radiotherapy Combined With ICIs for Advanced NSCLCNCT05754203 · 2023-08-01

Stereotactic Re-irradiation of Local Recurrences of Prostate Cancer After RadiotherapyNCT06201078 · 2023-07-31

Preoperative Boost Associated With Neoadjuvant Chemotherapy in Luminal B Breast CancerNCT05673304 · 2023-05-24

The Postoperative Radiotherapy in N1 Breast Cancer PatientsNCT05440149 · 2022-08-01

Observational Study on Extreme Hypofractionation for Localized Prostate CancerNCT05344235 · 2022-04-25

Serial MRI Scans During Radiation TherapyNCT04188535 · 2020-01-15

Ultra Hypofractionnated Radiotherapy With HDR Brachytherapy Boost.NCT05786742 · 2014-04-01

Centrally Confined 8Gy/1f to Tumor Core Followed by Concurrent Chemoradiotherapy for Unresectable Stage III NSCLCNCT07523464 · 2026-06-01

NOT_YET_RECRUITING

Effects of Moderate-intensity Interval Aerobic Exercise (MIIAE) on Inflammatory, Immune, Metabolic, Physical Fitness, and Quality of Life Parameters in Breast Cancer Patients Undergoing Radiotherapy.NCT07583719 · 2026-06-01

NOT_YET_RECRUITING

Phase III, Multicenter, Randomized Controlled Clinical Study of Three-Dimensional Radiotherapy for Primary Tumors in Non-Oligometastatic Stage IV Non-Small Cell Lung CancerNCT07462728 · 2026-03-30

NOT_YET_RECRUITING

Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung CancerNCT05909137 · 2026-02-01

NOT_YET_RECRUITING

A Phase 2 Randomized, Controlled Trial of QL1706 Plus Chemotherapy and Quad Shot for Driver Gene-negative Advanced Non-small Cell Lung Cancer.NCT07271602 · 2026-01-30

NOT_YET_RECRUITING

Immediate Autologous Tissue Breast Reconstruction and Radiotherapy Strategy After Breast Cancer SurgeryNCT07798466 · 2025-09-01

ENROLLING_BY_INVITATION

Artificial Intelligence-based Voice Assessment of Children and Adults Respiratory ConditionsNCT06630078 · 2024-11-30

NOT_YET_RECRUITING

HOBBIT 3: Mental Exercises and Temporal AlterationNCT06100068 · 2023-11-27

A Phase II Study of T-DXd Plus SRT in HER2-positive Breast Cancer Brain MetastasesNCT06088056 · 2023-11-01

Autologous Fat Infiltration Versus General Measures as Treatment in Radiodermatitis Induced for Radiotherapy in Breast Cancer PatientsNCT07023796 · 2023-09-01

Prospective Comparative Study for Patients With Biochemical Recurrence Prostate Cancer Detecting by 18F-JK-PSMA-7NCT05622162 · 2022-12-19

Telephone Paramedical Support Prior to the Radiotherapy Simulation Scanner for Patients with Prostate CancerNCT05910229 · 2022-11-09

Neoadjuvant Triprizumab and Radiotherapy in Operable Patients With Stage IIA-IIIA Non-small Cell Lung CancerNCT06065813 · 2022-08-08

Durvalumab Combined With Consolidation Radiotherapy After First-line Treatment in Extensive Stage Small Cell Lung Cancer With OligometastasesNCT05484583 · 2022-08-01

NOT_YET_RECRUITING

Respiratory Training and Relaxation Techniques to Improve Adjuvant Radiation Therapy in DIBH in Breast CancerNCT05975190 · 2022-06-22

Hypofractionated LocoRegional Radiotherapy in Breast CancerNCT04228991 · 2021-02-10

ACTIVE_NOT_RECRUITING

A Randomized Study of Primary Tumor Radiotherapy for Patients With Stage Ⅳ NSCLCNCT04654520 · 2020-12-15

Exercise Therapy During RadiotherapyNCT04507789 · 2020-10-10

Effect of Irradiation Doses < 10 Gy and of Irradiated Bone Volume on the Variation of Blood Elements of the Complete Blood Count During and After Pelvic IrradiationNCT04626466 · 2020-08-03

Artificial Intelligence for Prostate Cancer Treatment PlanningNCT04441775 · 2020-06-22

Feasibility and Safety of Physical Exercise in Men With Prostate CancerNCT04500080 · 2020-04-14

12 Fractions Carbon Ion Radiotherapy for Localized Prostate CancerNCT04724577 · 2019-12-01

Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer PatientsNCT03870919 · 2019-10-23

ACTIVE_NOT_RECRUITING

PD-1 Inhibitors Consolidation in Extensive-stage Small Cell Lung CancerNCT03971214 · 2019-06-01

Health Status of Women With Breast CancerNCT03761940 · 2019-03-14

NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 TherapyNCT03589339 · 2019-01-16

ACTIVE_NOT_RECRUITING

Stereotactic Radiotherapy With Different Fractionation Modes for the Early Lung CancerNCT05802641 · 2018-01-07

Whole Breast + Lymph Node Irradiation: Prone Compared to Supine Position in 15 or 5 FractionsNCT03280719 · 2017-09-15

Twice-daily SIB Radiotherapy Versus Standard Radiotherapy for Patients With SCLCNCT03214003 · 2017-06-30

Addition of Radiotherapy to Standard Medical Treatment for Stage IV NSCLCNCT04530708 · 2017-02-01

To Evaluate the Role of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung CancerNCT02977169 · 2016-11-01

To Evaluate the Optimal Timing of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung CancerNCT02974426 · 2016-11-01

Comparison Between Endovascular and Bronchoscopic Tumor Marker Insertion for Real-time Stereotactic-guided Radiotherapy in Lung CancerNCT04684186 · 2016-10-10

Abscopal Effect for Metastatic Non-small Cell Lung Cancer.NCT02542930 · 2016-01-01

Abscopal Effect for Metastatic Small Cell Lung CancerNCT02542137 · 2015-09-01

Evaluation of the Immunological Effects of a Combined Treatment With Radiation and Cyclophosphamide in Metastasized Breast Cancer PatientsNCT02441270 · 2015-04-01

Highly Accelerated Dose-Integrated Radiotherapy in 5 Fractions in Breast CancerNCT04098926 · 2015-01-01

Radiation Pneumonitis After SBRT for NSCLCNCT02428049 · 2013-10-01

Common interventions

RadiotherapyRADIATION3 CTV omitted or delineatedRADIATION2 Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)DRUG2 Stereotactic Body RadiotherapyRADIATION2 Thoracic radiotherapyRADIATION2 ThymalfasinDRUG2 AccelerationRADIATION1 AdebrelimabDRUG1 AI-assisted RT modellingOTHER1 Autologous fat filtrationPROCEDURE1 Biological investigationsOTHER1 Breast Radiotherapy with or without Deep Inspiration Breath Hold (DIBH)RADIATION1 Bronchoscopic fiducial marker insertionPROCEDURE1 carbon ion radiotherapyRADIATION1 CarboplatinDRUG1 Centrally Confined 8 Gy/1 Fraction Immune-Priming Radiotherapy to the Tumor Core Followed by Definitive Concurrent ChemoradiotherapyRADIATION1 ChemotherapyDRUG1 Chinese herbal medicine decoctionDRUG1 CisplatinDRUG1 Combination use of SRT with T-DXdDRUG1 Concurrent RadiochemotherapyCOMBINATION_PRODUCT1 Consolidation radiotherapyRADIATION1 Conventional segmental radiotherapyRADIATION1 CyclophosphamideDRUG1 Dose-integrated accelerated EBRT in pN+ breast cancerRADIATION1

Leading sponsors

University Hospital, Ghent 4 Fudan University 3 Shanghai Chest Hospital 3 Guizhou Medical University 2 Hubei Cancer Hospital 2 Ontario Clinical Oncology Group (OCOG) 2 Peking University Cancer Hospital & Institute 2 Xinqiao Hospital of Chongqing 2 Zhejiang Provincial People's Hospital 2 Affiliated Cancer Hospital & Institute of Guangzhou Medical University 1 Anhui Provincial Hospital 1 Anhui Shi, MD 1 Azienda USL Reggio Emilia - IRCCS 1 Centre Hospitalier Universitaire Vaudois 1 Chinese Academy of Medical Sciences 1

Trial status mix

RECRUITING22

UNKNOWN14

COMPLETED12

NOT_YET_RECRUITING7

WITHDRAWN4

ACTIVE_NOT_RECRUITING3

ENROLLING_BY_INVITATION1

TERMINATED1

Phase mix

NA23

PHASE217

PHASE37

PHASE13

EARLY_PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.